Management of Acute Severe Colitis in Children With Ulcerative Colitis in the Biologics Era

Abstract

BACKGROUND AND OBJECTIVE: Approximately one-third of children with ulcerative colitis will experience at least 1 attack of acute severe colitis (ASC) before 15 years of age. Severe disease can be defined in children when Pediatric Ulcerative Colitis Activity Index is >65 and/or ≥6 bloody stools per day, and/or 1 of the following: tachycardia, fever, anemia, and elevated erythrocyte sedimentation rate with or without systemic toxicity. Our aim was to provide practical suggestions on the management of ASC in children. The goal of medical therapy is to avoid colectomy while preventing complications of disease, side effects of medications, and mortality. METHODS: A systematic search was carried out through Medline via PubMed to identify all articles published in English to date, based on the following keywords “ulcerative colitis,” “pediatric ulcerative colitis,” “biological therapy,” and “acute severe colitis.” Multidisciplinary clinical evaluation is recommended to identify early nonresponders to conventional treatment with intravenous corticosteroids, and to start, if indicated, second-line therapy or “rescue therapy,” such as calcineurin inhibitors (cyclosporine, tacrolimus) and anti–tumor necrosis factor molecules (infliximab). RESULTS: Pediatric Ulcerative Colitis Activity Index is a valid predictive tool that can guide clinicians in evaluating response to therapy. Surgery should be considered in the case of complications or rapid clinical deterioration during medical treatment. CONCLUSIONS: Several pitfalls may be present in the management of ASC, and a correct clinical and therapeutic approach is recommended to reduce surgical risk.

Azathioprine dosing and metabolite measurement in pediatric inflammatory bowel disease: does one size fit all?

“…These are reliable indicators of disease severity and remission status and are helpful in evaluating the response to treatment changes. An AI score of <10 accurately reflects clinical remission [6,7].…”

Histamine drives severity of innate inflammation via histamine 4 receptor in murine experimental colitis

“… 2 While these therapeutic advances in treating adaptive immune pathways have revolutionized UC patient outcomes, one in four patients still require colectomy, urging elucidation of other mechanisms that drive inflammation. 3 , 4 …”

Tacrolimus for ulcerative colitis in children: a multicenter survey in Japan

“…In our study, the rate of remission or response at 2 weeks was 85.1%, and the clinical remission rate was 47.8% within 2 weeks. Pediatric UC is characterized by more extensive and rapid progression than adult-onset UC, and pediatric patients are more likely to have acute severe exacerbations and lack of response to steroid therapy [1-4,16]. The steroid failure rate was reported as 34%; therefore, especially in severe cases, second-line therapy should be introduced at an appropriate time to avoid or delay colectomy [4-6].…”